Diammonium Glycyrrhizinate
drugOn this page
Also known as Diammonium glycyrrhizate
Summary
Diammonium Glycyrrhizinate (CHEMBL4297742) is a phase-3 clinical-stage unknown; indicated across 2 conditions including chronic hepatitis b virus infection and autoimmune thrombocytopenic purpura.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 2 conditions
- Clinical trials: 3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297742 |
| Name | Diammonium Glycyrrhizinate |
| Type | Unknown |
| Max phase | 3 |
Also known as: Diammonium glycyrrhizate, Diammonium glycyrrhizinate, DIAMMONIUM GLYCYRRHIZINATE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| chronic hepatitis B virus infection | 3 | MONDO:0005366 | EFO:0004239 |
| autoimmune thrombocytopenic purpura | 2 | MONDO:0008558 | EFO:0007160 |
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 1 |
| PHASE3 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03349008 | PHASE4 | UNKNOWN | Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B |
| NCT01342185 | PHASE3 | UNKNOWN | Efficacy of Medical Ozone Therapy in Patients With Chronic Hepatitis B |
| NCT01643447 | Not specified | COMPLETED | Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: chronic hepatitis B virus infection